Annual General Meeting - Trading Update

RNS Number : 2603D

Dechra Pharmaceuticals PLC

27 October 2020

 

Tuesday, 27 October 2020

Dechra^® Pharmaceuticals PLC

(Dechra, Group, Company)

Annual General Meeting

Trading update

The Board of Dechra issues the following statement prior to the Annual General Meeting (AGM) which will take place at the Company's offices at 6 Cheshire Avenue, Cheshire Business Park, Lostock Gralam, Northwich, CW9 7UA at 9.30 am today, Tuesday 27 October 2020:

Trading in the first quarter of the financial year has been stronger than expected however at this early stage of the year the ongoing effect of COVID-19 on our markets is not yet certain.

No other new trading updates are to be made at the AGM today.

Dechra will announce its interim results for the six month period to 31 December 2020 on 22 February 2021.

Enquiries:
Dechra Pharmaceuticals PLC
Ian Page, Chief Executive Officer	Office:  [phone]
Paul Sandland, Chief Financial Officer e-mail: [e-mail]	Office:  [phone]
TooleyStreet Communications Ltd
Fiona Tooley, Director e-mail: [e-mail]	Mobile: [phone] Office:  [phone]

About Dechra

Dechra is a global specialist veterinary pharmaceuticals and relates products business. Our expertise is in the development, manufacture, marketing, and sales of high quality products exclusively for veterinarians worldwide.  Dechra's business is unique as the majority of its products are used to treat medical conditions for which there is no other effective solution or have a clinical or dosing advantage over competitor products. 

For more information, please visit: www.dechra.com

Stock Code: Full Listing (Pharmaceuticals): DPH

LEI: 213800J4UVB5OWG8VX82

Trademarks

Dechra and the Dechra "D" logo are registered trademarks of Dechra Pharmaceuticals PLC.

Forward Looking Statement

This document may contain certain forward-looking statements. The forward-looking statements reflect the knowledge and information available to the Company during the preparation and up to the publication of this document.  By their very nature, these statements depend upon circumstances and relate to events that may occur in the future thereby involve a degree of uncertainty. Therefore, nothing in this document should be construed as a profit forecast by the Company.

 

END

 

 

AGMDGBDGIBDDGGL